Patents by Inventor Abburi Ramaiah

Abburi Ramaiah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9457064
    Abstract: Synergistic therapies for the treatment of vitiligo are provided, in which basic fibroblast growth factor peptide(s) lotion was developed as a new mode of therapy for the treatment of vitiligo. It went through various phases of successful clinical trials in India and is marketed by the drug controller general (India). It is effective in 80% of stable and segmental vitiligo. Data are provided which demonstrate that combinatorial treatment of vitiligo by local application of bFGF peptide(s) lotions in association with psoralens and UV-A, or steroids or surgical procedures, produce a synergistic response in which the rate of repigmentation increases synergistically and more efficacious results are obtained than with any one of them alone. Any combinatorial therapy comprising the local application of bFGF peptide(s) lotion on the vitiligo patch in combination with any other therapies for the treatment of vitiligo also may act synergistically.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: October 4, 2016
    Inventor: Abburi Ramaiah
  • Patent number: 8314065
    Abstract: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: November 20, 2012
    Inventor: Abburi Ramaiah
  • Publication number: 20100323962
    Abstract: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.
    Type: Application
    Filed: April 21, 2010
    Publication date: December 23, 2010
    Inventor: Abburi Ramaiah
  • Publication number: 20090069233
    Abstract: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.
    Type: Application
    Filed: September 11, 2006
    Publication date: March 12, 2009
    Inventor: Abburi Ramaiah
  • Publication number: 20070027080
    Abstract: Synergistic therapies for the treatment of vitiligo are provided. The major therapies for the treatment of vitiligo—a pigmentary disorder characterized by patchy depigmentation of skin are Psoralens plus UV-A, steroids. Basic fibroblast growth (bFGF) peptide lotion or surgical procedures. Psoralens plus UV-A is effective in about 50% of cases, steroids are limitedly effective only in fast spreading cases of vitiligo and often reoccurs on stoppage of treatment. Surgical treatment is the last resort for vitiligo therapy, when all other therapies failed. It is limitedly effective. Basic fibroblast growth factor peptide(s) lotion was developed as a new mode of therapy for the treatment of vitiligo. It went through successfully various phases of clinical trials in India and is allowed to be marketed by the drug controller general (India). It is effective in 80% of stable and in segmental vitiligo.
    Type: Application
    Filed: July 29, 2005
    Publication date: February 1, 2007
    Inventor: Abburi Ramaiah
  • Patent number: 6696417
    Abstract: A cosmetic skin/hair darkening composition for topical application to skin and/or hair is provided that comprises for 0.1 to 10% by weight of a peptide having an isoelectric point ranging from 6 to 11.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: February 24, 2004
    Assignee: Chesebrough-Pond's USA Co., division of Conopco, Inc.
    Inventors: Subramanian Raghupathi, Abburi Ramaiah, Govindarajan Raman, Sushama Shripad Wagh
  • Patent number: 6143723
    Abstract: This invention relates to a pigmentary agent for treatment of pigmentary isorers an also to a cosmetic preparation. Such a preparation does not require any exposure of the skin surface to sunlight. The invention also relates to a vehicle for peptides having a molecular weight of up to 1500.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: November 7, 2000
    Inventor: Abburi Ramaiah